1. Improving Compliance and Persistence with Bisphosphonate Therapy for Osteoporosis 
Ronald D. Emkey, MD, Mark Ettinger, MD 
The American Journal of Medicine 
Volume 119, Issue 4, Pages S18-S24 (April 2006)
DOI: /j.amjmed
Copyright © 2006 Elsevier Inc. Terms and Conditions

2. Figure 1
(A) Unrecognized vertebral fracture in women ≥60 years of age, hospitalized for various reasons (n=132 of 934). (B) Undertreatment of hip fracture for hospitalized patients (N=1,076) from 4 Midwestern hospitals. BP = blood pressure; DXA = dual X-ray absorptiometry. (Adapted from Osteoporos Int1 and Arthritis Rheum.2)
The American Journal of Medicine  , S18-S24DOI: ( /j.amjmed )
Copyright © 2006 Elsevier Inc. Terms and Conditions

3. Figure 2
Patients on existing bisphosphonate therapy who remained on therapy after 12 months. (Adapted from Arthritis Rheum.24)
The American Journal of Medicine  , S18-S24DOI: ( /j.amjmed )
Copyright © 2006 Elsevier Inc. Terms and Conditions

4. Figure 3
Changes in lumbar spine bone mineral density with daily risedronate (5 mg) and 2 formulations of once-weekly risedronate (35 mg and 50 mg). (Adapted from Calcif Tissue Int.28)
The American Journal of Medicine  , S18-S24DOI: ( /j.amjmed )
Copyright © 2006 Elsevier Inc. Terms and Conditions

5. Figure 4
Changes in lumbar spine bone mineral density (BMD) with daily ibandronate (2.5 mg) and 3 formulations of once-monthly ibandronate (50/50 mg, 100 mg, and 150 mg). ⁎P <0.001 vs daily regimen. (Adapted from “Once-monthly Oral Ibandronate Dosing Is Highly Efficacious in Postmenopausal Osteoporosis.”31)
The American Journal of Medicine  , S18-S24DOI: ( /j.amjmed )
Copyright © 2006 Elsevier Inc. Terms and Conditions